First human to receive transplanted pig kidney dies [Reuters]
Eledon Pharmaceuticals, Inc. (ELDN)
Company Research
Source: Reuters
"The Mass General transplant team is deeply saddened at the sudden passing of Mr. Rick Slayman," the hospital said in a statement on Saturday. "We have no indication that it was the result of his recent transplant." Slayman, 62, of Weymouth, Massachusetts, in March in a four-hour surgery that the hospital at the time called "a major milestone in the quest to provide more readily available organs to patients." "Our family is deeply saddened about the sudden passing of our beloved Rick but take great comfort knowing he inspired so many," Slayman's family said in a statement. Slayman had received a transplant of a human kidney at the same hospital in 2018 after seven years on dialysis, but the organ failed after five years and he had resumed dialysis treatments. The kidney was provided by eGenesis of Cambridge, Massachusetts, from a pig that had been genetically edited to remove genes harmful to a human recipient and add certain human genes to improve compatibility, according to
Show less
Read more
Impact Snapshot
Event Time:
ELDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELDN alerts
High impacting Eledon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ELDN
News
- Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation [Yahoo! Finance]Yahoo! Finance
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationGlobeNewswire
- Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]Yahoo! Finance
ELDN
Earnings
- 5/9/24 - Beat
ELDN
Analyst Actions
- 6/4/24 - HC Wainwright
ELDN
Sec Filings
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- ELDN's page on the SEC website